These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 30646796)

  • 1. Differential clinical significance of pre-, interim-, and post-treatment plasma Epstein-Barr virus DNA load in NK/T-cell lymphoma treated with P-GEMOX protocol.
    Wang XX; Li PF; Bai B; Gao Y; Rong QX; Cai QQ; Lin SX; Zhang YJ; Li ZM; Jiang WQ; Huang HQ
    Leuk Lymphoma; 2019 Aug; 60(8):1917-1925. PubMed ID: 30646796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.
    Wang L; Wang H; Wang JH; Xia ZJ; Lu Y; Huang HQ; Jiang WQ; Zhang YJ
    Oncotarget; 2015 Oct; 6(30):30317-26. PubMed ID: 26210287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma.
    Wei W; Wu P; Li L; Zhang ZH
    Hematology; 2017 Jul; 22(6):320-329. PubMed ID: 27917702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma.
    Cho J; Kim SJ; Park S; Yoo KH; Ki CS; Ko Y; Kim WS
    Ann Hematol; 2018 Aug; 97(8):1427-1436. PubMed ID: 29627879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential P-GEMOX and radiotherapy for early-stage extranodal natural killer/T-cell lymphoma: A multicenter study.
    Zhang Y; Ma S; Cai J; Yang Y; Jing H; Shuang Y; Peng Z; Li B; Liu P; Xia Z; Xia Y; Gao Y; Chen D; Lin J; Li Q; Xu S; Xu Q; Zhang H; Huang H; Cai Q
    Am J Hematol; 2021 Nov; 96(11):1481-1490. PubMed ID: 34449095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type.
    Ito Y; Kimura H; Maeda Y; Hashimoto C; Ishida F; Izutsu K; Fukushima N; Isobe Y; Takizawa J; Hasegawa Y; Kobayashi H; Okamura S; Kobayashi H; Yamaguchi M; Suzumiya J; Hyo R; Nakamura S; Kawa K; Oshimi K; Suzuki R
    Clin Cancer Res; 2012 Aug; 18(15):4183-90. PubMed ID: 22675173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma.
    Wang JH; Wang L; Liu CC; Xia ZJ; Huang HQ; Lin TY; Jiang WQ; Lu Y
    Oncotarget; 2016 May; 7(20):29092-101. PubMed ID: 27093153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma.
    Wang JH; Wang H; Wang YJ; Xia ZJ; Huang HQ; Jiang WQ; Lu Y
    Oncotarget; 2016 Jun; 7(23):35412-22. PubMed ID: 27072578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of patients treated with SVILE
    Wei L; Yang L; Ye J; Cong J; Li X; Yao N; Yang J; Cui X; Ding J; Wu Y; Wang J
    Cancer Biol Med; 2020 Aug; 17(3):795-804. PubMed ID: 32944407
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy.
    Wang ZY; Liu QF; Wang H; Jin J; Wang WH; Wang SL; Song YW; Liu YP; Fang H; Ren H; Wu RY; Chen B; Zhang XM; Lu NN; Zhou LQ; Li YX
    Blood; 2012 Sep; 120(10):2003-10. PubMed ID: 22826562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum EBV EA-IgA and VCA-IgA antibodies can be used for risk group stratification and prognostic prediction in extranodal NK/T cell lymphoma: 24-year experience at a single institution.
    Huang Y; Rao H; Yan S; Wang F; Wu Q; Feng Y; Zhang Y
    Ann Hematol; 2017 Aug; 96(8):1331-1342. PubMed ID: 28550598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients.
    Wang X; Hu J; Dong M; Ding M; Zhu L; Wu J; Sun Z; Li X; Zhang L; Li L; Wang X; Fu X; Wang G; Chen Q; Zhang M; Zhang X
    Clin Transl Sci; 2021 Jan; 14(1):405-411. PubMed ID: 33045134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerance of GELOXD/P-GEMOXD in newly diagnosed nasal-type extranodal NK/T-cell lymphoma: A multicenter retrospective study.
    Li JW; Li YJ; Zhong MZ; Liu XL; Li J; Li KL; Liu XY; Zhou F; OuYang Z; Sun ZY; Huang LJ; He JQ; Zhou H; Yi PY
    Eur J Haematol; 2018 Mar; 100(3):247-256. PubMed ID: 29194798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T/NK cell type chronic active Epstein-Barr virus disease in adults: an underlying condition for Epstein-Barr virus-associated T/NK-cell lymphoma.
    Isobe Y; Aritaka N; Setoguchi Y; Ito Y; Kimura H; Hamano Y; Sugimoto K; Komatsu N
    J Clin Pathol; 2012 Mar; 65(3):278-82. PubMed ID: 22247563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis.
    Kim SJ; Choi JY; Hyun SH; Ki CS; Oh D; Ahn YC; Ko YH; Choi S; Jung SH; Khong PL; Tang T; Yan X; Lim ST; Kwong YL; Kim WS;
    Lancet Haematol; 2015 Feb; 2(2):e66-74. PubMed ID: 26687611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type.
    Suzuki R; Yamaguchi M; Izutsu K; Yamamoto G; Takada K; Harabuchi Y; Isobe Y; Gomyo H; Koike T; Okamoto M; Hyo R; Suzumiya J; Nakamura S; Kawa K; Oshimi K;
    Blood; 2011 Dec; 118(23):6018-22. PubMed ID: 21984805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type.
    Xu PP; Xiong J; Cheng S; Zhao X; Wang CF; Cai G; Zhong HJ; Huang HY; Chen JY; Zhao WL
    EBioMedicine; 2017 Nov; 25():41-49. PubMed ID: 29056540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic evaluation of the prognostic value of
    Xu P; Guo R; You J; Cheng S; Li J; Zhong H; Sun C; Xu H; Huang H; Li B; Zhao W
    Ann Hematol; 2021 Apr; 100(4):1039-1047. PubMed ID: 33634350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating Epstein-Barr virus-encoded micro-RNAs as potential biomarkers for nasal natural killer/T-cell lymphoma.
    Komabayashi Y; Kishibe K; Nagato T; Ueda S; Takahara M; Harabuchi Y
    Hematol Oncol; 2017 Dec; 35(4):655-663. PubMed ID: 27709652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent peripheral blood EBV-DNA positive with high expression of PD-L1 and upregulation of CD4 + CD25 + T cell ratio in early stage NK/T cell lymphoma patients may predict worse outcome.
    Li PF; Mao YZ; Bai B; Gao Y; Zhang YJ; Li ZM; Jiang WQ; Huang HQ
    Ann Hematol; 2018 Dec; 97(12):2381-2389. PubMed ID: 30116872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.